Dillon Newman

If those with the most demanding jobs don’t treat their bodies traditionally, why should the average individual?

NeuroAge is a longevity biotech startup that creates drugs to rejuvenate the brain and treat neurodegenerative disorders, including Alzheimer’s disease. We sat down with the CEO to learn more.

In the latest addition to our interview series, we sit down with Cole Kirschner, the visionary CEO and co-founder of AgeRate. In this interview, Cole shares the origin story of his direct-to-consumer longevity startup, which uses blood tests to reveal to consumers how well they are aging and give them the tools and knowledge they ...

In June of this year, a new company was teased at the 4th Longevity Therapeutics Summit that had researchers and investors alike buzzing. Presented by none other than Dr. Matt Kaeberlein, this new company – named Ora Biomedical – focused on high-throughput drug screening using robotics and AI. But although the company sounded interesting and ...

Hevolution Foundation, the behemoth non-profit with an annual $1 billion budget, this week released a new grant program to fund aging-related research that has been overlooked. The pilot program – Hevolution Foundation – Advancing Geroscience Efforts (HF-AGE) – plans to fund ten longevity projects with up to $5 million in 2022.  The goal of HF-AGE ...

The field of longevity only continues to grow. With funding rounds and research efforts ramping up, slowly but surely, the industry is beginning to detach itself from the broad world of biotech. What’s not so obvious, however, is which companies and founders are blazing the path forward. To help bridge this gap, Spannr will be ...

Brian Armstrong, CEO of one of the world’s largest crypto exchanges, Coinbase (COIN), announced on Twitter this week his intention to sell 2% of his personal company holdings to further fund scientific research, including his longevity company NewLimit. Armstrong on Friday tweeted: “I’m passionate about accelerating science and tech to help solve some of the ...

Since the mid-1700s, underwriters have been predicting human lifespan and mortality rate to manage the risk associated with providing life insurance. For more than 200 years, very little changed in regards to how medical underwriters determined longevity risk. That was until the introduction of blood collection in the 1980s when insurance companies grappled with the ...

Although 2022 has been a record breaking year for longevity funding with billions of dollars already pouring in, much of the funding has been relegated to a small, select group of companies. These companies have the potential to change the longevity landscape as we know it, however, there is always a risk of too much ...